Fresenius Kabi agreed to acquire Akorn for $34.00/share in cash, an enterprise value of approximately $4.75B (~$4.3B equity). The deal would have expanded Fresenius Kabi's U.S. specialty generics injectables and ophthalmic franchise. Fresenius terminated the merger in April 2018 over alleged Akorn FDA data integrity breaches; Delaware Chancery Court upheld termination via material adverse effect ruling in October 2018.
Key facts
AnnouncedApr 24, 2017
Deal value$4.8B
Deal typeAcquisition/Merger
Therapeutic areaMultiple (specialty/generics)
IndicationsMultiple (specialty/generics)
Key assetsSpecialty generics injectable, ophthalmic and topical portfolio